By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
In order to diagnose, monitor, or treat medical disorders, the term “medical imaging” refers to a number of different technologies that are used to see the human body. Each technology type provides distinct information regarding the part of the body being investigated or treated, in relation to potential illness, damage, or the efficacy of medical care.
France medical imaging market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Incepto, a new platform on the market, gives doctors and hospitals access to a range of AI-based solutions that are intended to boost the accuracy of diagnoses and free up time for medical teams without requiring them to switch out equipment.
Incepto is raising €27 million today to support its expansion across Europe. With participation from Wille Finance, AXA Venture Partners, the Patient Autonome fund of Bpifrance, and Karista, the financing round is being led by LBO France’s Venture – Digital Health team.
With this financing, Incepto enters a new phase as it introduces its product in four new European nations (Germany, Spain, Italy and Portugal).
Four new subsidiaries were created as part of the development of Incepto.increase the number of medical imaging programmes it offers for oncology, orthopaedics, rheumatology, emergency care, and pneumology.
Incepto is addressing important public health issues by expanding its geographic reach and growing its suite of applications. This includes lowering exam wait times, addressing the shortage of specialists for some serious diseases, and assisting doctors as they deal with the mounting mountain of data that needs to be analysed.
Incepto has three strategic goals in light of the booming AI market in Europe:choosing and making available the most potent AI imaging solutions for each specialty while ensuring the highest standards of quality;Developing with physicians new software solutions that address unmet needs: As a result, Incepto’s first jointly developed products are ARVA and KEROS.
Intravascular Imaging Incorporated (“i3”) Announces Launch of Its 3-French NIRF-IVUS Imaging Catheter.Using its patented NIRF-IVUS intravascular imaging system, the device was evaluated in ex vivo human coronary arteries and in vivo in preclinical studies.
I3’s imaging system combines near-infrared fluorescence imaging (“NIRF”) with intravascular ultrasound (“IVUS”), the primary imaging technique used for coronary stent optimization during percutaneous coronary intervention (PCI).
The molecular and cellular details that underlie the pathophysiologic progression of coronary lesions, arterial dissections, coronary transplant vasculopathy, and fibrin production in unhealed stents can be seen when NIRF-IVUS is combined into a single catheter. U
